New capabilities and simple, standard site
experience cut trial time and expense
Fixed price implementation to get up and
running quickly
Industry advances to connected trials as seven
of the top 20 biopharmas adopt Veeva Site Connect
BARCELONA, Spain, Sept. 5, 2024 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today announced, in a major step forward for clinical
trial execution, the newest release of Veeva Site Connect, adding
powerful new capabilities and a streamlined site-centric experience
to simplify and standardize sponsor-site collaboration. With Veeva
Site Connect, sponsors reduce the time and effort of site start-up,
study conduct, and closeout for higher-quality trials at a
significantly lower cost.
"By standardizing how information is shared across all sites in
one application with Veeva Site Connect, we aim to save time and
effort that can be focused on treating patients," said a clinical
operations excellence leader at a top 20 biopharma. "Our goal is to
eliminate manual handoffs and inefficiencies for faster site
start-up, more efficient monitoring, and simplified study
closeout."
To deliver better trial execution in less time, the expansion of
Veeva Site Connect includes major application and implementation
advances.
- New capabilities expand Site Connect beyond document
exchange and safety distribution: Veeva Site Connect adds Study
Communications, Contacts, Payment Information, and quick links to
sponsor systems to already powerful Document Exchange and Safety
Distribution capabilities.
- Optimized site user interface that's the same for all
trials: Organizing everything sites need in an intuitive site
homepage with simple sidebar navigation means sites can easily stay
informed and close out tasks in just a few clicks. Having the same
user experience for all trials gives sites a standard way to work
across sponsors.
- Open for use by any site, anywhere: Veeva Site Connect
is accessible for all sites everywhere. Sites that use Veeva
SiteVault as their eISF get the added benefit of connecting their
study for seamless bidirectional document exchange.
- Simple fixed price implementation to get up and running in
two to four months: With a standard fixed fee engagement of two
to four months, depending upon company size, sponsors can make a
big impact quickly toward their goal of faster, higher quality
trial execution.
"I would be ecstatic if all our sponsors use Veeva Site Connect.
It gives sites a much more efficient way to collaborate with
sponsors, maintain regulatory compliance, and get critical
therapies to patients faster," said Alisha
Garibaldi, CEO, Skylight Health Research. "The less time we
spend doing administrative work in systems, the more time we have
to execute trials and help patients."
"By implementing Veeva Site Connect for our safety letter
distribution process, we anticipate achieving a significant
reduction in manual processing while enhancing oversight and
compliance," said Marta
Jureczko-Hinzmann, head of global clinical solution services
at AstraZeneca. "Sharing safety letters across all sites globally
within a single application will allow us to harmonize the entire
process across the company and optimize how we allocate valuable
resources."
Veeva Site Connect is part of Veeva Clinical Platform, the
complete and connected solution supporting patients, sites, and
sponsors. Veeva Site Connect plays a critical role as the industry
moves to simplify and standardize site collaboration, and seven of
the top 20 biopharmas have already adopted Veeva Site Connect to
streamline trials.
See the Veeva Site Connect demo and learn more at Veeva R&D
and Quality Summit 9-10 September in Boston, where top biopharmas will share how
they use Veeva Site Connect to simplify trial execution for greater
quality and speed.
Additional Information
For more on Veeva Site Connect,
visit: veeva.com/eu/VeevaSiteConnect
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com/eu.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's
products and services and the expected results or benefits from use
of our products and services. These statements are based on our
current expectations. Actual results could differ materially from
those provided in this release and we have no obligation to update
such statements. There are numerous risks that have the potential
to negatively impact our results, including the risks and
uncertainties disclosed in our filing on Form 10-Q for the period
ended July 31, 2024 and in our
subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com
Video -
https://mma.prnewswire.com/media/2497162/Site_Connect_User_Experience_FINAL.mp4
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/major-release-of-veeva-site-connect-streamlines-clinical-trial-execution-for-sites-and-sponsors-302239008.html